The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Astellas Pharma Europe's Betmigatm (mirabegron) for the symptomatic treatment of urgency, increased micturition frequency ...
Tags: symptomatic treatment of urgency, pharmaceutical product
Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received FDA approval for its abbreviated new drug application (ANDA) of Trospium Chloride Extended-release Capsules. Watson anticipates beginning the shipment of the ...
Tags: FDA, Trospium Chloride Extended-release Capsules, pharmaceutical product
Pfizer Canada has introduced Toviaz (fesoterodine fumarate extended release tablets) that is indicated for the treatment of patients with overactive bladder (OAB) with symptoms of urinary frequency, urgency, or urge incontinence, or any ...
Tags: Pfizer Canada, Toviaz, overactive bladder, OAB
Teva UK has launched generic Tolterodine 1mg and 2mg film-coated tablets, and Tolterodine XL (Mariosea XL) 4mg capsules. Tolterodine is a generic version of Detrusitol (tolterodine) while Tolterodine XL (Mariosea XL) is a generic version ...
Tags: generic tolterodine, medicines, overactive bladder syndrome
Mylan and its subsidiary, Mylan Pharmaceuticals, have signed a settlement agreement with Pfizer, Pharmacia & Upjohn Company and Pfizer Health related to Detrol LA patent litigation. The litigation is related to Mylan Pharmaceuticals' ...
Astellas Pharma, a Japan-based pharmaceutical company, has announced its decision to shut down one of its subsidiaries, Urogenix, which is a research facility focusing on drug discovery in the field of urology. The company expects to ...
Tags: urology research, resource allocation, clinical potential
FOR IMMEDIATE RELEASE (Free-Press-Release.com) August 16, 2012 -- Skipton, North Yorkshire, 16 August 2012: Conforming to quality standards is bound to earn a business solid reputation. DeliverNet, which offers cleaning, medical equipment ...
Astellas Pharma has gained FDA approval for Myrbetriq (mirabegron) extended-release tablets for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. Myrbetriq is a once ...
Tags: FDA approval, pharmaceutical product, oral OAB treatment
BOTOX Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval. BOTOX Cosmetic is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe ...
Tags: BOTOX Cosmetic, 10-year anniversary, FDA, frown lines, glabellar lines
Watson Pharmaceuticals has confirmed favorable US District Court for the District of Delaware ruling in generic Sanctura XR (trospium chloride extended-release capsules) patent suit. The Court has ruled that the asserted claims of US ...
Tags: treatment of overactive bladder, pharmaceutical product